ERBB2 and neoplasm: Compared to the study by Shayeb et al.22, which focused primarily on assay performance, our analysis offers additional insights by incorporating a broader tumor-type breakdown and evaluating the prevalence and co-occurrence of pathogenic ERBB2 mutations.